Actively Recruiting
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Led by CHU de Quebec-Universite Laval · Updated on 2026-01-07
80
Participants Needed
1
Research Sites
203 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
CONDITIONS
Official Title
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with multiple myeloma
- At least 18 years old
- Have had one or more prior lines of therapy
- Currently receiving BCMA-directed T-cell engager therapy starting treatment
- May be on previous immunoglobulin support or not
You will not qualify if you...
- Under 18 years old
- Pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Intégré de Cancérologie
Québec, Quebec, Canada
Actively Recruiting
Research Team
P
Philippe Nadeau, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here